Richard A. Paulson net worth and biography

Richard Paulson Biography and Net Worth

President and Chief Executive Officer of Karyopharm Therapeutics

Mr. Paulson was appointed President and Chief Executive Officer of Karyopharm in May 2021 and has served as a member of Karyopharm’s Board of Directors since February 2020. He was previously an Executive Vice President of Ipsen Pharmaceuticals, Inc. and Chief Executive Officer of Ipsen North America, a global biopharmaceutical company focused on innovation and specialty care in areas of oncology, neuroscience and rare diseases, from February 2018 to May 2021. Mr. Paulson previously worked at Amgen for 10 years holding varying leadership positions across Europe and North America, including Vice President and General Manager of Amgen’s U.S. Oncology Business Unit, and prior to that served as the Vice President of Marketing for Amgen’s U.S. Oncology Business, General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to Amgen, Mr. Paulson held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Mr. Paulson also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada. He is a member of the board of directors of Bluebirdbio.

Mr. Paulson has an MBA from the University of Toronto, Canada and an undergraduate degree in commerce from the University of Saskatchewan, Canada.

What is Richard A. Paulson's net worth?: The estimated net worth of Richard A. Paulson is at least $721.49 thousand as of October 4th, 2024. Mr. Paulson owns 75,707 shares of Karyopharm Therapeutics stock worth more than $721,488 as of July 16th. This net worth approximation does not reflect any other investments that Mr. Paulson may own. Learn More about Richard A. Paulson's net worth.
How do I contact Richard A. Paulson?: The corporate mailing address for Mr. Paulson and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Richard A. Paulson's contact information.
Has Richard A. Paulson been buying or selling shares of Karyopharm Therapeutics?: Richard A. Paulson has not been actively trading shares of Karyopharm Therapeutics in the last ninety days. Most recently, Richard A. Paulson sold 240 shares of the business's stock in a transaction on Friday, October 4th. The shares were sold at an average price of $13.20, for a transaction totalling $3,168.00. Following the completion of the sale, the chief executive officer now directly owns 75,707 shares of the company's stock, valued at $999,332.40. Learn More on Richard A. Paulson's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Richard Paulson (President and Chief Executive Officer), Reshma Rangwala (Chief Medical Officer & Head of Research), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,958 shares worth more than $19,037.72. The most recent insider tranaction occured on April, 21st when EVP Reshma Rangwala sold 449 shares worth more than $4,014.06. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/21/2026.

Richard A. Paulson Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/4/2024	Sell	240	$13.20	$3,168.00	75,707
8/6/2024	Sell	240	$13.95	$3,348.00	76,192
7/5/2024	Sell	241	$12.75	$3,072.75	76,432
6/4/2024	Sell	239	$14.85	$3,549.15	76,673
5/6/2024	Sell	238	$16.95	$4,034.10	76,913
4/4/2024	Sell	237	$19.35	$4,585.95	77,151
3/5/2024	Sell	238	$19.50	$4,641.00	77,389
2/29/2024	Sell	5,364	$17.55	$94,138.20	78,918
2/6/2024	Sell	267	$23.85	$6,367.95	54,763
1/4/2024	Sell	274	$12.30	$3,370.20	52,231
12/4/2023	Sell	241	$11.85	$2,855.85	52,505
11/6/2023	Sell	240	$13.80	$3,312.00	52,746
10/4/2023	Sell	239	$19.05	$4,552.95	52,987
8/7/2023	Sell	248	$25.80	$6,398.40	53,467
7/5/2023	Sell	235	$25.80	$6,063.00	53,716
5/4/2023	Sell	253	$50.25	$12,713.25	54,187
4/4/2023	Sell	233	$59.55	$13,875.15	54,441
3/6/2023	Sell	233	$47.40	$11,044.20	54,674
3/1/2023	Sell	2,202	$45.45	$100,080.90	54,908
1/4/2023	Sell	261	$49.05	$12,802.05	40,573
12/5/2022	Sell	232	$77.55	$17,991.60	40,835
11/4/2022	Sell	232	$68.10	$15,799.20	41,067
10/4/2022	Sell	232	$88.05	$20,427.60	41,300
9/8/2022	Sell	231	$78.45	$18,121.95	41,533
8/4/2022	Sell	154	$67.20	$10,348.80	41,765
7/8/2022	Sell	141	$77.70	$10,955.70	41,919
6/7/2022	Sell	169	$86.40	$14,601.60	42,060

Richard A. Paulson Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $9.53

$9.38

$9.86

50 Day Range

MA: $9.15

$7.14

$10.67

2 Week Range

Now: $9.53

$3.65

$10.99

Volume

315,583 shs

Average Volume

518,590 shs

Market Capitalization

$215.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8